Single User License
INR 135860
Site License
INR 271720
Corporate User License
INR 407580

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Hyperphosphatemia-Pipeline Review, H1 2015

Hyperphosphatemia-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Hyperphosphatemia-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Hyperphosphatemia-Pipeline Review, H1 2015', provides an overview of the Hyperphosphatemia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hyperphosphatemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hyperphosphatemia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Hyperphosphatemia

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Hyperphosphatemia and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Hyperphosphatemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Hyperphosphatemia pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Hyperphosphatemia

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Hyperphosphatemia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Hyperphosphatemia Overview 7

Therapeutics Development 8

Pipeline Products for Hyperphosphatemia-Overview 8

Pipeline Products for Hyperphosphatemia-Comparative Analysis 9

Hyperphosphatemia-Therapeutics under Development by Companies 10

Hyperphosphatemia-Pipeline Products Glance 12

Late Stage Products 12

Clinical Stage Products 13

Early Stage Products 14

Hyperphosphatemia-Products under Development by Companies 15

Hyperphosphatemia-Companies Involved in Therapeutics Development 16

Astellas Pharma Inc. 16

AstraZeneca PLC 17

Medice Arzneimittel Putter GmbH & Co. KG 18

Mitsubishi Tanabe Pharma Corporation 19

OPKO Health, Inc. 20

Panion & Bf Biotech Inc 21

Sanofi 22

Spectrum Pharmaceuticals, Inc. 23

Toray Industries, Inc. 24

Vifor Pharma AG 25

Hyperphosphatemia-Therapeutics Assessment 26

Assessment by Monotherapy Products 26

Assessment by Target 27

Assessment by Mechanism of Action 29

Assessment by Route of Administration 31

Assessment by Molecule Type 32

Drug Profiles 34

ASP-3325-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

colestilan chloride-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Fe-SAMMS-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

fermagate-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

ferric citrate-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

JPH-101-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

niacinamide-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

PT-20-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

RDX-002-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

Small Molecules to Inhibit Phosphate Transport for Hyperphosphatemia In CKD-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

SPI-014-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

sucroferric oxyhydroxide-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

tenapanor hydrochloride-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

TRK-390-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

VS-501-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

VS-505-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

Hyperphosphatemia-Recent Pipeline Updates 57

Hyperphosphatemia-Dormant Projects 68

Hyperphosphatemia-Discontinued Products 69

Hyperphosphatemia-Product Development Milestones 70

Featured News & Press Releases 70

Feb 02, 2015: Ardelyx Reports Results from Phase 2b Clinical Trial Evaluating Tenapanor in Treating Hyperphosphatemia in Chronic Kidney Disease Patients on Hemodialysis 70

Jan 27, 2015: Velphoro receives Swissmedic approval for the treatment of hyperphosphatemia in adult patients with chronic kidney disease on dialysis 70

Jan 09, 2015: Keryx Biopharmaceuticals Turns to Veeva Commercial Cloud to Support First FDA-Approved Product Launch 71

Dec 04, 2014: Keryx Biopharmaceuticals Announces Issuance of a New U.S. Patent for Auryxia (ferric citrate) Covering Orally Administrable Forms 72

Nov 19, 2014: New Drug Application Submitted For PA21 (development code) For Treatment Of Hyperphosphatemia 73

Nov 17, 2014: Keryx Biopharmaceuticals Announces Trade Name Auryxia for Ferric Citrate 74

Nov 15, 2014: Keryx Biopharmaceuticals Announces Results From Ferric Citrate Phase 3 Long-Term Safety Extension Study 74

Oct 23, 2014: Ardelyx's Tenapanor Selected for Oral and Poster Presentations at the American Society of Nephrology's Kidney Week 2014 75

Oct 01, 2014: Keryx Biopharmaceuticals Announces Issuance of a New U.S. Patent for Ferric Citrate Covering Orally Administrable Forms 77

Sep 05, 2014: Keryx Biopharmaceuticals Receives FDA Approval of Ferric Citrate, a New, Oral Iron-Based Treatment for Dialysis Patients With Hyperphosphatemia 77

Appendix 79

Methodology 79

Coverage 79

Secondary Research 79

Primary Research 79

Expert Panel Validation 79

Contact Us 79

Disclaimer 80

List of Tables

Number of Products under Development for Hyperphosphatemia, H1 2015 8

Number of Products under Development for Hyperphosphatemia-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 11

Comparative Analysis by Late Stage Development, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 13

Comparative Analysis by Early Stage Development, H1 2015 14

Products under Development by Companies, H1 2015 15

Hyperphosphatemia-Pipeline by Astellas Pharma Inc., H1 2015 16

Hyperphosphatemia-Pipeline by AstraZeneca PLC, H1 2015 17

Hyperphosphatemia-Pipeline by Medice Arzneimittel Putter GmbH & Co. KG, H1 2015 18

Hyperphosphatemia-Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2015 19

Hyperphosphatemia-Pipeline by OPKO Health, Inc., H1 2015 20

Hyperphosphatemia-Pipeline by Panion & Bf Biotech Inc, H1 2015 21

Hyperphosphatemia-Pipeline by Sanofi, H1 2015 22

Hyperphosphatemia-Pipeline by Spectrum Pharmaceuticals, Inc., H1 2015 23

Hyperphosphatemia-Pipeline by Toray Industries, Inc., H1 2015 24

Hyperphosphatemia-Pipeline by Vifor Pharma AG, H1 2015 25

Assessment by Monotherapy Products, H1 2015 26

Number of Products by Stage and Target, H1 2015 28

Number of Products by Stage and Mechanism of Action, H1 2015 30

Number of Products by Stage and Route of Administration, H1 2015 31

Number of Products by Stage and Molecule Type, H1 2015 33

Hyperphosphatemia Therapeutics-Recent Pipeline Updates, H1 2015 57

Hyperphosphatemia-Dormant Projects, H1 2015 68

Hyperphosphatemia-Discontinued Products, H1 2015 69

List of Figures

Number of Products under Development for Hyperphosphatemia, H1 2015 8

Number of Products under Development for Hyperphosphatemia-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Comparative Analysis by Late Stage Development, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 13

Comparative Analysis by Early Stage Products, H1 2015 14

Assessment by Monotherapy Products, H1 2015 26

Number of Products by Top 10 Targets, H1 2015 27

Number of Products by Stage and Top 10 Targets, H1 2015 27

Number of Products by Top 10 Mechanism of Actions, H1 2015 29

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 29

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 31

Number of Products by Top 10 Molecule Types, H1 2015 32

Number of Products by Stage and Top 10 Molecule Types, H1 2015 33

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Astellas Pharma Inc.

AstraZeneca PLC

Medice Arzneimittel Putter GmbH & Co. KG

Mitsubishi Tanabe Pharma Corporation

OPKO Health, Inc.

Panion & Bf Biotech Inc

Sanofi

Spectrum Pharmaceuticals, Inc.

Toray Industries, Inc.

Vifor Pharma AG

Hyperphosphatemia Therapeutic Products under Development, Key Players in Hyperphosphatemia Therapeutics, Hyperphosphatemia Pipeline Overview, Hyperphosphatemia Pipeline, Hyperphosphatemia Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com